News | May 30, 2013

Clinical Data Demonstrates TriGuard TAVI Embolic Protection Device Reduces Brain Lesion Volume

May 30, 2013 — Cerebral function is the essence of quality of life. Its preservation throughout medical procedures is a key component to procedural success and patient care. New scientific data presented at the annual EuroPCR Congress in Paris heightens the spreading understanding and recognition that protecting the brain and preserving brain reserve is an important goal of transcatheter aortic valve replacement (TAVR) and other cardiovascular procedures. 

The first report on the DEFLECT-I clinical trial was presented at EuroPCR, during the Hot-Line - First-in-man in Valvular Heart Disease session by M. Mullen, M.D., the PI of the study. The TriGuard device is designed to minimize the risk of brain damage associated with cardiovascular procedures and was used to filter the embolic material from brain circulation during TAVR. The results demonstrate an impressive reduction of new brain lesion volume during TAVR when performed with the TriGuard Cerebral Protection Device when compared to unprotected procedures (historical data):

  • Maximum single lesion volume in DEFLECT-I was 17 times smaller than the average in the reported literature (0.39 vs. 6.45 cm3), representing a 94 percent reduction.
  • Maximum total lesion volume in DEFLECT-I was 95 percent smaller than the maximum total lesion volume in reported studies (3.94 vs. 70.3 cm3).
  • Average (mean) single lesion volume in DEFLECT-I was 65 percent smaller than the average of reported historical data (0.12 vs. 0.34 cm3), and average total lesion volume was 57 percent smaller than reported average total lesion volume in reported historical data (0.7 vs. 1.64 cm3). 

 

In addition, the brain protection by TriGuard was safe, with no device related adverse events, had no interference with TAVR procedure, and performed optimally covering all three cerebral branches in 87 percent of the cases throughout valve replacement.

TriGuard, the only embolic protection device designed to cover all aortic cerebral branches, is fashioned to accommodate various anatomical variations of the aortic arch.

Keystone Heart's presence at EuroPCR, Europe's largest professional meeting specializing in interventional cardiovascular medicine, was greeted with great interest.  Focus on cardiovascular procedure related brain damage, clinically evident and silent stroke, and potential preventative measures was emphasized in additional sessions, as well as in non-affiliated scientific presentations throughout the course and congress.

Keystone Heart's Scientific Advisory Board Meeting was held adjacent to EuroPCR.  Participating key opinion leaders reached unanimous agreement on a number of issues:

  • Stroke is a devastating adverse event after cardiovascular procedures
  • Systemic therapy is highly unlikely to prevent strokes related to dislodgement of calcified material and valve particles
  • Mechanical protection such as filters or deflection devices should be incorporated into the procedures to protect the brain from ischemic insults
  • DEFLECT-I results demonstrate great promise and value of cerebral protection

"The issue of stroke is one of the key areas of development for enhancing procedural safety in TAVR and other invasive treatments in cardiology," said Jeffrey Moses, M.D., Columbia University in New York. "The preliminary data from the TriGuard MRI study points to this technology as a potential solution to this important issue"

The TriGuard Cerebral Protection Device is an investigational device and not commercially available.

For more information: www.keystoneheart.com

Related Content

Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Siemens Healthineers Receives FDA Clearance for TrueFusion Structural Heart Disease Feature
Technology | Cardiovascular Ultrasound| September 06, 2017
The U.S. Food and Drug Administration (FDA) has cleared TrueFusion, a new cardiovascular application from Siemens...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
Abbott Initiates U.S. Pivotal Study of Amplatzer Device for Patent Ductus Arteriosus
News | Congenital Heart| September 05, 2017
Abbott announced it has initiated a U.S. pivotal clinical study evaluating the safety and effectiveness of a modified...
World's First Successful 52-mm Transcatheter Tricuspid Valve Implantation Completed in Italy
News | Heart Valve Technology| August 31, 2017
NaviGate Cardiac Structures Inc. (NCSI) announced that its Gate catheter-guided tricuspid atrioventricular valved stent...
Sponsored Content | Videos | Heart Valve Technology| August 30, 2017
Azeem Latib, M.D., MBBCh, FCP, interventional cardiologist at Columbus Hospital in Milan, Italy, discusses the latest
Overlay Init